An evaluation of the pharmacokinetics and clinical use of vinorelbine for NSCLC treatment.

Item

http://www.wikidata.org/entity/Q38109229

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

An evaluation of the pharmacok ...... norelbine for NSCLC treatment.

@en

type

Item

label

An evaluation of the pharmacok ...... norelbine for NSCLC treatment.

@en

prefLabel

An evaluation of the pharmacok ...... norelbine for NSCLC treatment.

@en

P1476

An evaluation of the pharmacok ...... norelbine for NSCLC treatment.

@en

P2093

Antonello Veccia

http://www.w3.org/2001/XMLSchema#string

Enzo Galligioni

http://www.w3.org/2001/XMLSchema#string

Mariachiara Dipasquale

http://www.w3.org/2001/XMLSchema#string

Orazio Caffo

http://www.w3.org/2001/XMLSchema#string

Viviana Murgia

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.

P304

1037-1051

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17425255.2013.804065

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23705788

http://www.w3.org/2001/XMLSchema#string